SCHEMBL3542145

SCHEMBL3542145

NC(=O)N(N)c1ccccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.40
CES1 P23141 2/20 0.40
PARP10 Q53GL7 1/20 0.40
KCNN4 O15554 5/20 0.38
ALDH1A1 P00352 3/20 0.38
ALOX15 P16050 1/20 0.38
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
GAA P10253 3/20 0.35
KCNE1 P15382 1/20 0.34
KCNQ1 P51787 1/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
TDP1 Q9NUW8 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28172033 0.84 TSHR (0.40) PARP10ALDH1A1SMN1; SMN2L3MBTL1GAA
SCHEMBL4726035 0.83 TDP1 (0.41) CES2CES1KCNN4ALDH1A1ALOX15
SCHEMBL30883191 0.81 L3MBTL1 (0.43) CES2CES1PARP10KCNN4ALDH1A1
SCHEMBL14053250 0.78 CES2 (0.39) CES2CES1PARP10KCNN4ALDH1A1
SCHEMBL5490028 0.78 DDB1 (0.46) CES2CES1KCNN4ALDH1A1ALOX15
SCHEMBL9234329 0.77 CYP3A4 (0.38) ALDH1A1ALOX15SMN1; SMN2L3MBTL1GAA
SCHEMBL11381825 0.76 CA1 (0.50) ALDH1A1SMN1; SMN2GAATDP1KMT2A
SCHEMBL20405982 0.76 PARP1 (0.37) CES2CES1PARP10KCNN4ALOX15
SCHEMBL28084119 0.76 DGAT1 (0.32) CES2CES1PARP1
SCHEMBL28084080 0.76 KCNN4 (0.31) KCNN4ALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 CES2 191/4885CES1 156/4885PARP10 3414/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 CES2 229/4885CES1 147/4885PARP10 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.